{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:47:29Z","timestamp":1791982049582,"version":"4.4.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["brainanddevelopment.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Brain and Development"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.braindev.2026.104601","type":"journal-article","created":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T12:05:58Z","timestamp":1791201958000},"page":"104601","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term real-world outcomes of nusinersen treatment in patients with spinal muscular atrophy types I\u2013III"],"prefix":"10.1016","volume":"48","author":[{"given":"Gulshan","family":"Aliyeva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sezan","family":"Mergen K\u0131l\u0131\u00e7","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuhal","family":"Yap\u0131c\u0131","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u0131nar","family":"Topalo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.braindev.2026.104601_bb0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s13023-017-0724-z","article-title":"Indirect estimation of the prevalence of spinal muscular atrophy type I, II, and III in the United States","volume":"12","author":"Lally","year":"2017","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.braindev.2026.104601_bb0010","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-017-0671-8","article-title":"Prevalence, incidence and carrier frequency of 5q\u2013linked spinal muscular atrophy\u2013a literature review","volume":"12","author":"Verhaart","year":"2017","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.braindev.2026.104601_bb0015","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2399\/prn.22.0301012","article-title":"Carrier frequency of spinal muscular atrophy in Turkish population","volume":"30","author":"Akar","year":"2022","journal-title":"Perinat J"},{"issue":"1","key":"10.1016\/j.braindev.2026.104601_bb0020","doi-asserted-by":"crossref","DOI":"10.1038\/s41572-022-00380-8","article-title":"Spinal muscular atrophy","volume":"8","author":"Mercuri","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.braindev.2026.104601_bb0025","doi-asserted-by":"crossref","first-page":"100878","DOI":"10.1016\/j.spen.2021.100878","article-title":"Spinal muscular atrophy","volume":"37","author":"Nicolau","year":"2021","journal-title":"Semin Pediatr Neurol"},{"issue":"3","key":"10.1016\/j.braindev.2026.104601_bb0030","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.nmd.2009.11.014","article-title":"The Children\u2019s Hospital of Philadelphia infant test of neuromuscular disorders (CHOP INTEND): test development and reliability","volume":"20","author":"Glanzman","year":"2010","journal-title":"Neuromuscul Disord"},{"issue":"9\u201310","key":"10.1016\/j.braindev.2026.104601_bb0035","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.nmd.2007.05.009","article-title":"An expanded version of the Hammersmith functional motor scale for SMA II and III patients","volume":"17","author":"O\u2019Hagen","year":"2007","journal-title":"Neuromuscul Disord"},{"issue":"4","key":"10.1016\/j.braindev.2026.104601_bb0040","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1474-4422(20)30037-5","article-title":"Nusinersen in adults with 5q spinal muscular atrophy: a non-interventional, multicentre, observational cohort study","volume":"19","author":"Hagenacker","year":"2020","journal-title":"Lancet Neurol"},{"issue":"8","key":"10.1016\/j.braindev.2026.104601_bb0045","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/acn3.51411","article-title":"Nusinersen in pediatric and adult patients with type III spinal muscular atrophy","volume":"8","author":"Pera","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"issue":"11","key":"10.1016\/j.braindev.2026.104601_bb0050","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp-2020-323822","article-title":"Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3","volume":"91","author":"Maggi","year":"2020","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.braindev.2026.104601_bb0055","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1186\/s13023-021-02065-z","article-title":"Motor function in type 2 and 3 SMA patients treated with Nusinersen: a critical review and meta-analysis","volume":"16","author":"Coratti","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.braindev.2026.104601_bb0060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s13023-023-02769-4","article-title":"Long-term nusinersen treatment across a wide spectrum of spinal muscular atrophy severity: a real-world experience","volume":"18","author":"\u0141usakowska","year":"2023","journal-title":"Orphanet J Rare Dis"},{"issue":"5","key":"10.1016\/j.braindev.2026.104601_bb0065","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s40120-024-00653-2","article-title":"Effectiveness of Nusinersen in adolescents and adults with spinal muscular atrophy: systematic review and Meta-analysis","volume":"13","author":"Hagenacker","year":"2024","journal-title":"Neurol Ther"},{"issue":"5","key":"10.1016\/j.braindev.2026.104601_bb0070","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nmd.2022.02.001","article-title":"Evaluation of real-life outcome data of patients with spinal muscular atrophy treated with nusinersen in Switzerland","volume":"32","author":"Tscherter","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.braindev.2026.104601_bb0075","doi-asserted-by":"crossref","first-page":"108983","DOI":"10.1016\/j.clineuro.2025.108983","article-title":"Real-world data on the effect of long-term treatment with nusinersen over> 4 years in a cohort of Swiss patients with spinal muscular atrophy","volume":"255","author":"Tscherter","year":"2025","journal-title":"Clin Neurol Neurosurg"},{"issue":"7","key":"10.1016\/j.braindev.2026.104601_bb0080","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1007\/s10072-023-06698-9","article-title":"Nusinersen for adults with spinal muscular atrophy","volume":"44","author":"Arslan","year":"2023","journal-title":"Neurol Sci"}],"container-title":["Brain and Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760426001026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0387760426001026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T12:03:53Z","timestamp":1791979433000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0387760426001026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":16,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,12]]}},"alternative-id":["S0387760426001026"],"URL":"https:\/\/doi.org\/10.1016\/j.braindev.2026.104601","relation":{},"ISSN":["0387-7604"],"issn-type":[{"value":"0387-7604","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term real-world outcomes of nusinersen treatment in patients with spinal muscular atrophy types I\u2013III","name":"articletitle","label":"Article Title"},{"value":"Brain and Development","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.braindev.2026.104601","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104601"}}